Wegovy is covered only when your plan has chosen to cover it, and for commercial plans that choice is still the exception rather than the rule. In KFF’s 2025 employer survey, the share of firms covering these drugs primarily for weight loss ranged from 16% to 43%, rising with firm size[3].
Wegovy is Novo Nordisk's semaglutide approved for weight, and its label also covers heart-risk reduction and a liver disease, which matters because a plan can treat those uses differently from weight loss. The label lists all three indications[2]. The maker’s prices, dose by dose, are in the Wegovy cost guide.
| Coverage | Does it pay for Wegovy? | What you pay if not |
|---|---|---|
| Employer or other commercial plan | Only if the plan chose to cover it; many do not | Self-pay, from $349 a pen box |
| Medicaid | Up to the state: federal law lets states exclude weight-loss drugs | Self-pay; the copay card excludes government plans |
| Medicare | Through the GLP-1 Bridge, at $50 a month, for those who qualify | Self-pay; the copay card excludes government plans |
Employer and commercial plans
KFF asked firms with 200 or more workers whether their largest plan covered GLP-1 drugs used primarily for weight loss in 2025[3]. The answer depended heavily on size:
- Firms with 200 to 999 workers: 16% covered them[3].
- Firms with 1,000 to 4,999 workers: 30% covered them[3].
- Firms with 5,000 or more workers: 43% covered them[3].
Coverage can come with conditions. Among covering firms, 34% required enrollees to meet with a dietitian, case manager or therapist, or to join a lifestyle program[3]. Those figures describe firms, not workers, so they tell you how common coverage is rather than what your own plan does.
To find out what your plan does, Novo Nordisk points patients to its coverage lookup tool or to calling the plan directly[1]. If the plan does not cover Wegovy, it offers a sample letter your clinician can use to ask your employer’s human resources department for coverage[1].
Medicaid
Medicaid is decided state by state. The federal statute lists drug classes a state may exclude from coverage or restrict, and the first item on that list is agents used for anorexia, weight loss or weight gain[4]. So a state may cover Wegovy for weight, restrict it, or leave it out, and the answer comes from your state’s Medicaid program.
The maker’s copay card is not a way around that, because government beneficiaries are excluded from it[1].
Medicare
Medicare works differently, through a separate program. The GLP-1 Bridge started July 1, 2026 and covers Wegovy injection or tablet at $50 a month, whatever your income[5]. Who qualifies, and how the heart-risk indication fits in, is set out in does Medicare cover Wegovy.
If your plan covers it: the copay card
With commercial coverage, the maker’s savings offer lets you pay as little as $25 a month, with savings capped at $100 a month[1]. A month means one box of 4 pens or one bottle of 30 tablets[1]. What the cap does to a high-deductible plan is worked through in the Wegovy savings card guide.
If it does not: the self-pay fallback
Without coverage, the maker’s standing self-pay price for the pen is $349 a month from 0.25 mg to 2.4 mg[1]. The tablet starts at $149 a month at its lowest dose[1]. The full dose-by-dose ladder is in the Wegovy cost guide.
The one question to ask your plan is specific: is Wegovy on the formulary for your diagnosis, and what does the plan require before it pays? The broader picture for peptides is in the insurance guide.